Intermittent Claudication: Invasive Treatment Superior to Pharmacological Treatment?

Peripheral vascular disease is strongly associated to cardiovascular events and a negative impact on health status and quality of life. 

Claudicación Intermitente: ¿el tratamiento invasivo es superior al tratamiento farmacológico?

However, researchers are yet to determine the benefit of early intervention in patients presenting intermittent claudication, and whether it improves quality of life. 

At present, there is little information in this regard (CLEVER trial), and it remains unclear when is best to intervene.   

The PORTRAIT is an international prospective multicenter study including 1246 patients with intermittent claudication, 314 receiving early invasive treatment -PCI or surgery plus 3-month medical treatment after diagnosis vs. medical treatment alone. 

Health status and quality of life were assessed by the Peripheral Artery Questionnaire (PAQ).

Read also: High Risk of Bleeding after PCI: More Evidence for Short DAPT.

Mean age was 67. There were no differences in diabetes, hypertension, dyslipidemia, prior MI, stroke, CAD or cardiac failure. Neither were there differences as regards disease localization. CAD was more severe in patients undergoing early intervention (46% Ruherford III in the early intervention group vs. 21.9% in the medical treatment group).

At one-year followup, PAQ was superior in patients undergoing early invasive treatment vs patients receiving medical treatment alone. 

After propensity score matching, 297 patients were left to receive early invasive treatment vs. 703 who received medical treatment alone. 

Read also: Is IVUS Guided PCI a Common Technique?

After 12 months, PAQ improvement was maintained in patients undergoing early intervention 30.8±25.2 vs. 16.7±23.4 (p<0.001)    

Conclusion

Patients with intermittent claudication undergoing early invasive intervention saw significant improved health status at one year compared against patients receiving a non-invasive treatment. This information might facilitate decision making when treating these patients. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: One-Year Health Status Outcomes Following Early Invasive and Noninvasive Treatment in Symptomatic Peripheral Artery Disease.

Reference: Suveen Angraa, et al. Circ Cardiovasc Interv. 2022;15:e011506. DOI: 10.1161/CIRCINTERVENTIONS.121.011506.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Atherosclerotic renal artery stenosis (ARAS) represents one of the main causes of secondary hypertension (HTN) and is associated with a higher risk of renal...

Transcatheter Deep Vein Arterialization in Critical Limb Ischemia Without Revascularization Options

Chronic limb-threatening ischemia in patients without conventional revascularization options represents one of the most challenging scenarios within peripheral arterial disease, with 1-year major amputation...

Duration of Smoking Cessation and Risk of Amputation After Revascularization in Critical Limb Ischemia

Critical limb ischemia (CLI) is associated with high rates of amputation and mortality. Although smoking cessation improves outcomes after revascularization, the impact of the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...